{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,3]],"date-time":"2023-11-03T01:07:30Z","timestamp":1698973650273},"reference-count":22,"publisher":"Georg Thieme Verlag KG","issue":"22","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Dtsch Med Wochenschr"],"published-print":{"date-parts":[[2023,11]]},"abstract":"<jats:title>Was ist neu?<\/jats:title><jats:p>\n            Neuerungen \u2013 Klassifikation und Prognose Die WHO-2016-Klassifikation wurde durch die ICC und die Klassifikation der WHO 2022 abgel\u00f6st. Die beiden Klassifikationen weisen viele \u00c4hnlichkeiten auf; den gr\u00f6\u00dften Unterschied stellt der Blastengrenzwert dar. Seit 2022 steht der IPSS-M, der molekulare Aberrationen ber\u00fccksichtigt, zur Verf\u00fcgung und verbessert im Vergleich zum IPSS-R die Prognosegenauigkeit f\u00fcr das progressionsfreie \u00dcberleben und das Gesamt\u00fcberleben. Somit soll eine optimierte therapeutische Entscheidungsfindung erm\u00f6glicht werden.<\/jats:p><jats:p>\n            Neuerungen \u2013 Therapie 2020 wurde Luspatercept f\u00fcr transfusionsabh\u00e4ngige Patient*innen mit Ringsideroblasten \u00b1 einer SF3B1-Mutation zugelassen. Rezent konnte die \u00dcberlegenheit von Luspatercept in der ersten Linie gegen\u00fcber EPO gezeigt werden. Mit Imetelstat k\u00f6nnen wir in Zukunft ggf. eine neue Zweitlinientherapie f\u00fcr LR-MDS-Patient*innen nach Versagen von EPO anbieten. F\u00fcr High-Risk-Patient*innen ist die Therapie mit Azacitidin weiterhin der Therapiestandard \u2013 die Ergebnisse der Phase-III-Studien der Kombinationstherapien m\u00fcssen abgewartet werden.<\/jats:p>","DOI":"10.1055\/a-1968-3106","type":"journal-article","created":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T23:50:23Z","timestamp":1698969023000},"page":"1431-1436","source":"Crossref","is-referenced-by-count":0,"title":["Neueste Erkenntnisse zum myelodysplastischen Syndrom"],"prefix":"10.1055","volume":"148","author":[{"given":"Verena","family":"Petzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dominik","family":"Wolf","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"194","published-online":{"date-parts":[[2023,11,2]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.blre.2019.04.004","article-title":"Flaming and fanning: The Spectrum of inflammatory influences in myelodysplastic syndromes","volume":"36","author":"T Banerjee","year":"2019","journal-title":"Blood Rev"},{"key":"ref2","doi-asserted-by":"publisher","first-page":"1703","DOI":"10.1038\/s41375-022-01613-1","article-title":"The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic\/Dendritic Neoplasms","volume":"36","author":"JD Khoury","year":"2022","journal-title":"Leukemia"},{"key":"ref3","doi-asserted-by":"publisher","first-page":"1200","DOI":"10.1182\/blood.2022015850","article-title":"International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data","volume":"140","author":"DA Arber","year":"2022","journal-title":"Blood"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1056\/evidoa2200310","article-title":"Prediction of Risk for Myeloid Malignancy in Clonal Hematopoiesis","volume":"2","author":"LD Weeks","year":"2023","journal-title":"NEJM Evid"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"2488","DOI":"10.1056\/NEJMoa1408617","article-title":"Age-related clonal hematopoiesis associated with adverse outcomes","volume":"371","author":"S Jaiswal","year":"2014","journal-title":"N Engl J Med"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200008","article-title":"Molecular International Prognostic Scoring System for Myelodysplastic Syndromes","volume":"1","author":"E Bernard","year":"2022","journal-title":"NEJM Evid"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2011.35.6394","article-title":"New comprehensive cytogenetic scoring system for primary myelodysplastic syndromes (MDS) and oligoblastic acute myeloid leukemia after MDS derived from an international database merge","volume":"30","author":"J Schanz","year":"2012","journal-title":"J Clin Oncol"},{"key":"ref8","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1038\/nrc.2017.60","article-title":"Therapy-related myeloid neoplasms: when genetics and environment collide","volume":"17","author":"ME McNerney","year":"2017","journal-title":"Nat Rev Cancer"},{"key":"ref9","doi-asserted-by":"publisher","first-page":"1530","DOI":"10.1038\/s41375-023-01910-3","article-title":"Assessment and validation of the molecular international prognostic scoring system for myelodysplastic syndromes","volume":"37","author":"LE Aguirre","year":"2023","journal-title":"Leukemia"},{"key":"ref10","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1200\/JCO.22.01784","article-title":"Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes","volume":"41","author":"E Sauta","year":"2023","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJMoa061292","article-title":"Lenalidomide in the Myelodysplastic Syndrome with Chromosome 5q Deletion","volume":"355","author":"A List","year":"2006","journal-title":"N Engl J Med"},{"issue":"S 01","key":"ref12","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1182\/blood-2022-168718","article-title":"Evaluation of Lenalidomide (LEN) Vs Placebo in Non-Transfusion Dependent Low Risk Del(5q) MDS Patients. Final Results of Sintra-REV Phase III International Multicenter Clinical Trial","volume":"140","author":"F L\u00f3pez Cadenas","year":"2022","journal-title":"Blood"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1056\/NEJMoa1908892","article-title":"Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes","volume":"382","author":"P Fenaux","year":"2020","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1182\/bloodadvances.2020002177","article-title":"Development of luspatercept to treat ineffective erythropoiesis","volume":"5","author":"AS Kubasch","year":"2021","journal-title":"Blood Adv"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"568","DOI":"10.1182\/blood.2019001057","article-title":"Lack of Gdf11 does not improve anemia or prevent the activity of RAP-536 in a mouse model of b-thalassemia","volume":"134","author":"A Guerra","year":"2019","journal-title":"Blood"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"E204","DOI":"10.1002\/ajh.26960","article-title":"Real-world efficacy and safety of luspatercept and predictive factors of response in patients with lower risk myelodysplastic syndromes with ring sideroblasts","volume":"98","author":"L Lanino","year":"2023","journal-title":"Am J Hematol"},{"issue":"S 01","key":"ref17","doi-asserted-by":"crossref","first-page":"9808","DOI":"10.1182\/blood-2022-157486","article-title":"Characterization of Patients with Lower-Risk Myelodysplastic Syndromes Experiencing Long-Term Responses with Luspatercept in the MEDALIST Study","volume":"140","author":"U Platzbecker","year":"2022","journal-title":"Blood"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/S0140-6736(23)00874-7","article-title":"Efficacy and safety of luspatercept versus epoetin alfa in erythropoiesis-stimulating agent-naive, transfusion-dependent, lower-risk myelodysplastic syndromes (COMMANDS): interim analysis of a phase 3, open-label, randomised controlled trial","volume":"402","author":"U Platzbecker","year":"2023","journal-title":"Lancet"},{"issue":"S 01","key":"ref19","doi-asserted-by":"crossref","first-page":"1106","DOI":"10.1182\/blood-2022-169050","article-title":"Imetelstat Achieved Prolonged, Continuous Transfusion Independence (TI) in Patients with Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndrome (LR-MDS) Relapsed\/Refractory (R\/R) to Erythropoiesis Stimulating Agents (ESAs) within the IMerge Phase 2 Study","volume":"140","author":"U Platzbecker","year":"2022","journal-title":"Blood"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/S1470-2045(09)70003-8","article-title":"Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study","volume":"10","author":"P Fenaux","year":"2009","journal-title":"Lancet Oncol"},{"key":"ref21","doi-asserted-by":"crossref","first-page":"2429","DOI":"10.1200\/JCO.2002.04.117","article-title":"Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B","volume":"20","author":"LR Silverman","year":"2002","journal-title":"J Clin Oncol"},{"key":"ref22","doi-asserted-by":"publisher","first-page":"511","DOI":"10.1080\/10428194.2022.2140287","article-title":"Therapeutic approaches for the management of higher risk myelodysplastic syndromes","volume":"64","author":"C Wang","year":"2023","journal-title":"Leuk Lymphoma"}],"container-title":["DMW - Deutsche Medizinische Wochenschrift"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/www.thieme-connect.de\/products\/ejournals\/pdf\/10.1055\/a-1968-3106.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,2]],"date-time":"2023-11-02T23:51:10Z","timestamp":1698969070000},"score":1,"resource":{"primary":{"URL":"http:\/\/www.thieme-connect.de\/DOI\/DOI?10.1055\/a-1968-3106"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":22,"journal-issue":{"issue":"22","published-online":{"date-parts":[[2023,11,2]]},"published-print":{"date-parts":[[2023,11]]}},"URL":"https:\/\/doi.org\/10.1055\/a-1968-3106","archive":["Portico","CLOCKSS"],"relation":{},"ISSN":["0012-0472","1439-4413"],"issn-type":[{"value":"0012-0472","type":"print"},{"value":"1439-4413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,11]]}}}